Next Generation Thiazolyl Ketone Inhibitors of Cytosolic Phospholipase A2 α: from Synthesis to Chemotherapeutic Mechanism of Action
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 24 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A(2) α for targeted cancer therapyNature communications · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE251999_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1057046 and SRA study SRP480085. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 24 sample titles: 24 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7990979 1hr, DMSO,biorep1, RNASEQ
- GSM7990980 1hr, Torin1, biorep1, RNASEQ
- GSM7990981 1hr, AVX420, biorep1, RNASEQ
- GSM7990982 1hr, DMSO,biorep2, RNASEQ
- GSM7990983 1hr, Torin1, biorep2, RNASEQ
- GSM7990984 1hr, AVX420, biorep2, RNASEQ
- GSM7990985 6hr, DMSO, biorep1, RNASEQ
- GSM7990986 6hr, AVX420, biorep1, RNASEQ
- GSM7990987 6hr, DMSO, biorep2, RNASEQ
- GSM7990988 6hr, AVX420, biorep2, RNASEQ
- GSM7990989 16hr, DMSO, biorep1, RNASEQ
- GSM7990990 16hr, AVX420, biorep1, RNASEQ
- GSM7990991 16hr, DMSO, biorep2, RNASEQ
- GSM7990992 16hr, AVX420, biorep2, RNASEQ
- GSM7990993 1hr, DMSO,biorep1, RIBOSEQ
- GSM7990994 1hr, Torin1, biorep1, RIBOSEQ
- GSM7990995 1hr, AVX420, biorep1, RIBOSEQ
- GSM7990996 1hr, DMSO,biorep2, RIBOSEQ
- GSM7990997 1hr, Torin1, biorep2, RIBOSEQ
- GSM7990998 1hr, AVX420, biorep2, RIBOSEQ
- GSM7990999 6hr, DMSO, biorep1, RIBOSEQ
- GSM7991000 6hr, AVX420, biorep1, RIBOSEQ
- GSM7991001 6hr, DMSO, biorep2, RIBOSEQ
- GSM7991002 6hr, AVX420, biorep2, RIBOSEQ
- GSE281556 Lysosomal sequestration of PARP inhibitors drives heterogeneous accumulation in ovarian cancer to increase efficacy 204 samples shares inhibitors
- GSE336781 ZFP36L2 orchestrates stress-adaptive plasticity in intestinal regeneration and colorectal cancer metastasis 93 samples shares generation
- GSE298758 DCPS modulates TDP-43 mediated neurodegeneration through P-body regulation [RNA-seq] 36 samples shares generation
- GSE309697 Generation of a Comprehensive Epigenomic Atlas in Clear Cell Renal Cell Carcinoma Informs Kidney Cancer Progression and Heritability 265 samples shares generation
- GSE222196 Treatment of prostate cancer cell lines with Androgen Receptor and Receptor Tyrosine Kinase inhibitors 246 samples shares inhibitors
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares inhibitors
- GSE305227 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [Quant-seq] 149 samples shares inhibitors
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares inhibitors
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.